Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease by Brandner, Sebastian et al.
Central and peripheral pathology of kuru:
pathological analysis of a recent case
and comparison with other forms of human
prion disease
Sebastian Brandner
1, Jerome Whitﬁeld
1,2,3, Ken Boone
2, Anderson Puwa
2,
Catherine O’Malley
1, Jacqueline M. Linehan
1, Susan Joiner
1,
Francesco Scaravilli
1, Ian Calder
1, Michael P. Alpers
1,2,3,
Jonathan D. F. Wadsworth
1 and John Collinge
1,*
1MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,
National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
2Papua New Guinea Institute of Medical Research, PO Box 60, Goroka, EHP 441, Papua New Guinea
3Centre for International Health, ABCRC, Shenton Park Campus, Curtin University,
GPO Box U1987, Perth, WA 6845, Australia
While the neuropathology of kuru is well deﬁned, there are few data concerning the distribution of
disease-related prion protein in peripheral tissues. Here we report the investigation of brain and
peripheral tissues from a kuru patient who died in 2003. Neuropathological ﬁndings were compared
with those seen in classical (sporadic and iatrogenic) Creutzfeldt–Jakob disease (CJD) and variant
CJD (vCJD). The neuropathological ﬁndings of the kuru patient showed all the stereotypical changes
that deﬁne kuru, with the occurrence of prominent PrP plaques throughout the brain.
Lymphoreticular tissue showed no evidence of prion colonization, suggesting that the peripheral
pathogenesis of kuru is similar to that seen in classical CJD rather than vCJD. These ﬁndings now
strongly suggest that the characteristic peripheral pathogenesis of vCJD is determined by prion strain
type alone rather than route of infection.
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1. INTRODUCTION
Prion diseases are fatal neurodegenerative disorders that
include Creutzfeldt–Jakob disease (CJD), Gerstmann–
Stra ¨ussler–Scheinker disease, fatal familial insomnia,
kuru and variant CJD (vCJD) in humans (Collinge
2005; Wadsworth & Collinge 2007). Their central
feature is the post-translational conversion of host-
encoded, cellular prion protein (PrP
C) to an abnormal
isoform, designated PrP
Sc (Prusiner 1982; Collinge
2001; Collinge & Clarke 2007). Human prion diseases
are biologically unique in that the disease process can
be triggered through inherited germ line mutations in
the human prion protein gene (PRNP), infection (by
inoculation, or in some cases by dietary exposure) with
prion-infected tissue or by rare sporadic events that
generate PrP
Sc (Prusiner 1998; Collinge 2001, 2005;
Weissmann 2004; Wadsworth & Collinge 2007).
Substantial evidence indicates that an abnormal PrP
isoform is the principal, if not the sole, component of
the transmissible infectious agent, or prion (Prusiner
1998; Collinge 2001; Weissmann 2004; Collinge &
Clarke 2007).
Kuru provides our principal experience of an
epidemic human prion disease and affected the Fore
linguistic group of the Eastern Highlands of Papua New
Guinea and to a lesser extent neighbouring groups with
whom the Fore intermarried (Zigas & Gajdusek 1959;
Alpers 1987; Collinge & Palmer 1997; Mead et al.2 0 0 3 ;
Collinge et al.2 0 0 6 ). It was the practice in these
communities to engage in consumption of dead relatives
as a mark of respect and mourning (transumption).
Kuru was the ﬁrst human prion disease shown to be
transmissible, by inoculation of non-human primates
with autopsy-derived braintissue (Gajdusek et al.1 9 6 6 ).
Consistent with the hypothesis that kuru originated
from chance consumption of an individual with
sporadic CJD (sCJD; Alpers & Rail 1971), molecular
and biological strain typing studies have shown that
kuru prions have molecular strain types (Parchi et al.
1997, 2000; Wadsworth et al. 2008a) and transmission
properties (Brown et al. 1994; Wadsworth et al. 2008a)
equivalent to those of classical (sporadic and iatro-
genic) CJD prions rather than vCJD prions or inherited
forms of prion disease (Wadsworth et al. 2008c).
Despite these data, both the clinical presentation and
the neuropathology of kuru are distinct from the
majority of patients with sCJD. In contrast to a rapidly
progressive dementia that is seen in most cases of sCJD
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2001, 2005; Hill et al. 2003; Wadsworth et al. 2003;
Collins et al. 2006), kuru presents with progressive
cerebellar ataxia with dementia appearing as a later and
less prominent feature (Alpers 1987; Brown et al. 1994;
Collinge & Palmer 1997; Collinge 2005; Collinge et al.
2006; although see Collinge et al. (2008) for clinical
review of recent cases). Moreover, although the
neuropathological changes seen in kuru lie within
the spectrum of those seen in sCJD, unicentric PrP
plaques are unusually prominent and widespread
(Hainfellner et al. 1997; McLean et al. 1998). As a
progressive cerebellar syndrome and the occurrence of
kuru-type plaques reminiscent of kuru are also notable
features of iatrogenic CJD resulting from peripheral
exposure to sCJD prions (Brown et al. 1992, 2000,
2006; Billette de Villemeur et al. 1994; Will 2003), it
appears that the cerebellar onset and subsequent
neuropathological changes in kuru may be signiﬁcantly
determined by peripheral routes of infection (predom-
inantly dietary), rather than by prion strain type
(Wadsworth et al. 2008a).
Although the pathological consequences of prion
infection occur in the central nervous system (CNS)
and experimental transmission of these diseases is most
efﬁciently accomplished by intracerebral inoculation,
natural infections do not occur by these means.
Administration to sites other than the CNS is known
to be associated with much longer incubation periods
(Brown et al. 2000; Collinge 2001), and kuru demon-
strates that human prion disease incubation periods
may extend to 50 years or more (Collinge et al. 2006).
Experimental evidence suggests that this latent period
is associated with clinically silent prion replication in
lymphoreticular or other tissues, whereas neuroinva-
sion takes place later (Kimberlin & Walker 1988;
Fraser et al. 1992; Aguzzi 2003). Distinct forms of
prion disease show differences in lymphoreticular
involvement that may be related to the aetiology of
the disease or to the divergent properties of distinct
prion strains (Collinge & Clarke 2007). For example,
the tissue distribution of PrP
Sc in vCJD differs stri-
kingly from that in classical CJD or inherited prion
disease with uniform and prominent involvement of
lymphoreticular tissues (Hill et al. 1999, 2006; Wads-
worth et al. 2001; Glatzel et al. 2003; Head et al. 2004;
Hilton et al. 2004; Joiner et al. 2005; Wroe et al. 2006).
The extensive peripheral pathogenesis seen in vCJD
raises concerns that iatrogenic transmission of vCJD
prions may be a major public health issue (Collinge
1999, 2001, 2005; Wadsworth & Collinge 2007) and
disturbingly, cases of blood transfusion-associated
vCJD prion infection have now emerged (Llewelyn
et al. 2004; Peden et al. 2004; Wroe et al. 2006).
To date, although the neuropathology of kuru is well
deﬁned (Fowler & Robertson 1959; Klatzo et al. 1959;
Neumann et al. 1964; Beck & Daniel 1965; Kakulas
et al. 1967; Hainfellner et al. 1997; Lantos et al. 1997;
McLean et al. 1998), there are few data concerning the
distribution of abnormal PrP deposition or prion
infectivity in peripheral tissues in kuru (Brown et al.
1994). Here, we now describe the investigation of
disease-related PrP in both the brain and the lympho-
reticular tissues of a kuru patient who died in 2003.
2. MATERIAL AND METHODS
(a) Research governance
Collection, storage and analysis of human tissue sampleswere
performed with consent from relatives and local community
leaders. Ethical approval for these studies was obtained from
the Local Research Ethics Committee of UCL Institute of
Neurology/National Hospital for Neurology and Neurosur-
gery and the Medical Research Advisory Committee of the
Government of Papua New Guinea.
(b) Immunohistochemistry
Brain and peripheral tissues were analysed with anti-glial
ﬁbrillary acidic protein (GFAP), rabbit polyclonal antiserum
and anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd,
London, UK), using a Ventana automated immunohisto-
chemical staining machine (Ventana Medical Systems, Inc.,
Tucson, AZ), as described previously (Frosh et al. 2004;
Wadsworth et al. 2008b). Tissue was ﬁxed in 10% buffered
formol saline followed by incubation in 98% formic acid for
1 hour. Following postﬁxation for 24 hours in 10% buffered
formol saline, the tissue samples were processed through
graded alcohols and parafﬁn wax embedded. The sections
were cut at a nominal thickness of 4 mm, treated with 98%
formic acid for 5 min and then boiled in a low ionic strength
buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium
citrate, pH 7.8) for 20 min. Abnormal PrP accumulation
was examined using anti-PrP monoclonal ICSM 35 (D-Gen
Ltd) followed by a biotinylated anti-mouse IgG secondary
antibody (iView Biotinylated Ig, Ventana Medical Systems,
Inc.) and an avidin–biotin horseradish peroxidase conjugate
(iView SA-HRP, Ventana Medical Systems, Inc.) before
development with 30,3-diaminobenzedine tetrachloride as the
chromogen (iView DAB, Ventana Medical Systems Inc.).
Haematoxylin was used as the counter stain. Haematoxylin
and eosin (H&E) staining of serial sections was performed
using conventional methods. Appropriate controls were
used throughout.
(c) Immunoblotting
All procedures were carried out in a microbiological contain-
ment level 3 facility, with strict adherence to safety protocols.
Brain (frontal cortex) and peripheral tissues were prepared as
10% w/v homogenates in Dulbecco’s sterile phosphate
buffered saline lacking Ca
2C and Mg
2C ions using Duall
tissue grinders (Wadsworth et al. 2001, 2008b). Brain
homogenate was analysed, before or after proteinase K
digestion (50 mgm l
K1 ﬁnal protease concentration, 1 hour,
378C), by immunoblotting with anti-PrP monoclonal
antibody 3F4 using high sensitivity enhanced chemi-
luminescence (Wadsworth et al. 2001, 2008b). Peripheral
tissue homogenate was analysed by sodium phosphotungstic
acid precipitation of PrP
Sc, proteinase K digestion and
immunoblotting with anti-PrP monoclonal antibody 3F4
using high sensitivity enhanced chemiluminescence, as
described previously (Wadsworth et al. 2001, 2008b).
3. RESULTS
(a) Summary of clinical history
Detailed clinical description is given in Collinge et al.
(2008; patient KAW), but is also outlined here. The
patient was male and aged 58 years when examined in
September 2001. He had experienced episodes of pain
and weakness in the legs for several years, which had
made walking difﬁcult; these had initially responded
to local treatment but then recurred. He also had
3756 S. Brandner et al. Central and peripheral pathology of kuru
Phil. Trans. R. Soc. B (2008)headaches and pain in the neck, arms and thoracic and
abdominal muscles. He was convinced these were
‘attacks of kuru’. Frequent fasciculations in his calf
muscles, a steady posture, ﬁrm stance and normal gait
were noted. He was born in 1943 and lived in the South
Fore continuously during the period when traditional
mortuary feasts were held. His mother died of kuru in
1965 and local oral history conﬁrmed his participation
in multiple mortuary feasts as a child.
On his return from a month of travelling in the
highlands, he complained of unsteadiness of gait,
which slowly worsened. Over the next 10 months, he
followed a progressive course with worsening cerebellar
ataxia typical of kuru and by the end of August 2002
had entered the second (sedentary) stage. After three
months, he was unable to sit without support and
became recumbent (stage 3 of kuru). He alternated
between periods of confusion and lucidity. He was
examined approximately a month after he became
recumbent when he was well nourished and in no pain.
He was lucid and able to converse sensibly. He was
calm and rational, with some ﬂattening of affect. He
had insight into his disease and said that his only worry
was what would happen to his children after he died.
He was continent of urine and faeces and without
pressure sores. He had severe photophobia and
pronounced cerebellar dysarthria. Eye movements
were full but jerky, with no nystagmus; there were no
abnormal facial movements or dysconjugate eye move-
ments. He was able to sit up only with external support
and had marked truncal instability. His hands were
held clasped in front to suppress involuntary postural
tremors. He had plastic, jerky rigidity of all four limbs.
His legs were weak and power in the arms and hands
was also reduced to grade 3 out of 5. Tendon reﬂexes
were diminished or absent; plantar responses were
ﬂexor. There was dysmetria in ﬁnger and hand
movements, intention tremor in ﬁnger-nose alternation
and dysdiadochokinesis. He performed all these tests
without hesitation or confusion.
His physical condition progressively declined and he
became incontinent, developed pressure sores in his
sacral area, in both buttocks and on both heels, and
dislocated his left hip. He ate very little and subsisted
largely on sips of water. He was unable to speak but
continued to make eye contact and followed people
with his eyes. He persisted in this state for another four
months. In April 2003, he lost consciousness for a day
but by the next dayhad regained the visual awareness of
his surroundings and again made eye contact; the only
movement was of his eyes. He remained in this state for
3 days. He was totally moribund the next day and died
the following day. PRNP analysis demonstrated normal
coding sequence and the codon 129 genotype was M/V.
(b) Tissue collection and macroscopic ﬁndings
Autopsy was performed locally. After opening the skull,
the brain was removed, and the brain stem and the
cerebellum were separated from the forebrain at mid-
brain level. The forebrain was then divided sagittally.
The left hemisphere was divided further and repre-
sentative samples were frozen. The right forebrain
and a small portion of the cerebellar hemisphere were
ﬁxed in formalin. A large number of somatic organs
including lymphoreticular tissue were also collected,
either frozen or formalin ﬁxed. All tissue samples
were shipped to the MRC Prion Unit, UCL Institute
of Neurology.
The formalin-ﬁxed hemisphere excluding the brain-
stem and the cerebellum weighed 430 g. The cerebral
cortex appeared normally conﬁgured, and no other
abnormalities were seen. The brain was sectioned in
coronal sections of approximately 1 cm thickness,
starting at the level of the mammillary bodies. The
coronal slices showed a cortical ribbon of normal
width, well demarcated from the underlying white
matter which appeared normal, and although no
apparent atrophy was seen, the brain appeared
generally small. The caudate, putamen, globus pal-
lidus, thalamus and subthalamic nucleus, and the
amygdala as well as the hippocampus appeared
macroscopically normal. The ventricular system was
of normal appearance, with indication of hydro-
cephalus ex vacuo. Pons, medulla, cerebellar cortex
and white matter and the dentate nucleus were not
available for examination, but a section of inferior
brainstem including olives was available and appeared
normal. The small sample of the cerebellar hemisphere
(25 g) did not show macroscopic abnormalities.
Representative brain regions were sampled, including
several neocortical areas (frontal, temporoparietal
and occipital cortex; ﬁgure 1a–g), hippocampus
(ﬁgure 1k,o–q), deep grey matter structures (caudate
nucleus (ﬁgure 1a,h–j) and thalamus on two levels
(ﬁgure 1k–n)), cerebellum (ﬁgure 3a–d), brain stem
(level of olives; ﬁgure 3e–h) and spinal cord (cervical
and lumbar; ﬁgure 3i–l).
4. NEUROPATHOLOGICAL FINDINGS
(a) Frontal cortex
Two adjacent regions of the frontal cortex were
examined (area rostral to the tip of the temporal
lobe): spongiform degeneration was generally mild to
moderate, with ﬁne vacuolation (ﬁgure 1b), which was
occasionally conﬂuent (ﬁgure 1e). In the H&E stained
sections, occasional amyloid plaques were identiﬁed.
Gliosis (assessed by immunohistochemical stainings
using anti-GFAP antiserum; ﬁgure 1c,f ) was brisk and
showed diffuse ﬁbrillary gliosis in the white matter and
individual stellate astrocytes in the grey matter.
Abnormal PrP was present as synaptic deposits when
present at low density and at higher density formed
dense plaques, which varied in size, ranging from small
dense granules to plaques of up to 30 mm in diameter
(ﬁgure 1d,g).
Analysis of frontal cortex brain homogenate by
immunoblotting after limited proteinase K digestion
demonstrated the presence of type 3 PrP
Sc (ﬁgure 2),
which we have previously observed in sporadic and
iatrogenic CJD (Collinge et al. 1996; Wadsworth et al.
1999; Hill et al. 2003) and in kuru (Wadsworth et al.
2008a,c).
(b) Caudate nucleus
The caudate nucleus was examined at two levels (level
of the nucleus accumbens and level of the anterior
commissure). Here, spongiform degeneration was far
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were often conﬂuent, indicating widespread neuronal
death (ﬁgure 1h). This spongiform degeneration was
seen across the entire grey matter of the caudate
nucleus. In correlation with the severe degeneration,
gliosis was more substantial with brisk astrocytic
reaction (ﬁgure 1i). PrP deposits were mainly synaptic
with occasional formation of small plaques. The white
matter structures contained only ﬁne granular deposits
of abnormal PrP (ﬁgure 1j ).
(c) Thalamus
Several thalamic nuclei (level of subthalamic nucleus
and pulvinar) showed a moderate spongiosis but a
more severe neuronal loss than the caudate nucleus
(ﬁgure 1l). This led to a compaction of the grey matter,
with surviving astrocytes being the main population.
This is reﬂected by a very dense ﬁbrillary gliosis
throughout (ﬁgure 1m). Abnormal PrP accumulated
as dense synaptic deposits, which often became
conﬂuent to form dense plaque-like structures
(ﬁgure 1n). These were most accentuated in areas of
severe neuronal loss and spongiform degeneration.
However, large classical kuru-type PrP plaques were
not seen (ﬁgure 1n).
(d) Hippocampus
The hippocampus was examined at the level of the
lateral geniculate nucleus, showing the ribbon of
the dentate gyrus and Ammon’s horn, extending to
(a)
(k)
(b) (c) (d)
(g) (f) (e)
(h)
(l)
(o) (p) (q)
(m) (n)
(i) (j)
caudate
frontal cortex
H&E GFAP PrP
thalamus
hippocampus
Figure 1. Pathological changes in several kuru forebrain regions. Multiple areas were examined and exhibited a highly variable
degree ofspongiform changes, gliosis and intensity and typeofPrPdeposition. (a) Samplingoffrontal cortex and caudate region in
a coronal brain slice, anterior third of the brain slice. (b–d)a n d( e–g) Two cortical areas with variable degree of spongiform
degeneration, and moderate gliosis. As with most other cortical areas, there is a variable degree of synaptic PrP deposition and
small dense plaques. (a,h–j ) Caudate nucleus and (k–n) thalamus show a more signiﬁcant spongiform degeneration (h,l)w i t h
more severe neuronal loss. This is accompanied by severe astrocytic reaction (gliosis; i,m). As in the cortex, there is a synaptic PrP
deposition and a variable PrP plaque load ( j,n). The hippocampus (k,o–q) is relatively mildly affected. There is almost no
spongiformchange(o)andthereareonlyveryoccasionaldensePrPplaqueswithnosynapticPrPdeposition(q).Thereis,however,
some astrocytic reaction (p). Scale bar, 120 mm.
36
30
16
kDa
sCJD
sCJD
kuru
2
MM
3
MV
3
VV
PrPSc type
codon 129
Figure 2. Frontal cortex homogenates from the kuru patient
and sCJD control samples of known PrP
Sc type were digested
with proteinase K and analysed by enhanced chemi-
luminescence using anti-PrP monoclonal antibody 3F4.
The provenance of each brain sample is designated above
each lane and the type of PrP
Sc detected in each sample
(using the London classiﬁcation of human PrP
Sc types;
Collinge et al. 1996; Hill et al. 2003) and the PRNP codon
129 genotype of the patient (M, methionine; V, valine) are
designated below.
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spared by the various pathological changes seen else-
where in the brain. Occasional spongiform vacuoles
were seen in the stratum radiatum and in the hilus
(ﬁgure 1o), and some mild spongiosis in the entorhinal
cortex. There was no neurodegeneration in the dentate
gyrus and Ammon’s horn (ﬁgure 1o). Accordingly, there
was relatively little gliosis, this being restricted mainly to
the stratum radiatum (ﬁgure 1p). PrP was deposited
as occasional small circumscribed plaques, but there
w a sa l m o s tn od e t e c t a b l es y n a p t i cP r P( ﬁgure 1q).
(e) Cerebellum
One section of the cerebellum, including the dentate
nucleus, was analysed. Here, the most signiﬁcant
pathological changes were seen in the molecular layer,
extending to the Purkinje cell layer, but not in the
internal granular layer (ﬁgure 3a–d). Amyloid plaques
were occasionally seen in the internal granular layer
(ﬁgure 1b). Gliosis was dense ﬁbrillary in the white
matter and less pronounced in the molecular layer
(ﬁgure 3c). Only occasional kuru plaques were seen in
the internal granular layer, between Purkinje cells and
in the molecular layer (ﬁgure 3d).
(f ) Brain stem
A section of the brain stem at the level of the olive was
available for analysis. There was remarkably little
spongiosis (ﬁgure 3f ); however, a dense ﬁbrillary
gliosis was seen throughout the white and grey matter
structures (ﬁgure 3g). Abnormal PrP was seen
predominantly as synaptic deposits in the grey matter
structures, such as the olivary nucleus. Small (micro)
PrP plaques were seen in both the grey and white
matter (ﬁgure 3h).
(g) Spinal cord
We examined the spinal cord at cervical (ﬁgure 3i,j),
thoracic (not shown) and lumbar levels (ﬁgure 3k,l).
There was virtually no pathological abnormality
detectable on the H&E stained sections, but staining
for abnormal PrP revealed occasional small plaques in
the grey matter of the anterior (ﬁgure 3i,j ) or posterior
horn (ﬁgure 3k,l).
(h) Spinal roots
We examined spinal nerve roots for the presence of
abnormal PrP and found minute PrP deposits associ-
ated with axons, possibly representing intra-axonal PrP
(not shown).
(i) Comparison of PrP plaque morphology in
kuru and other human prion diseases
Figure 4 shows comparison of the typical PrP plaque
pattern seen in the present kuru patient with cases of
sCJD, iatrogenic CJD and vCJD. Propagation of type 3
PrP
Sc 129 MV in sCJD, iatrogenic CJD and kuru share
fundamental histopathological patterns, showing a
propensity of PrP to aggregate into plaques of variable
size, ranging from small granules to medium-sized solid
plaques (ﬁgure 4b–d). There was no particular
accentuation around these plaques, and they were
distinct from the ﬂorid PrP plaques (ﬁgure 4e,f ) that
are the neuropathological hallmark of vCJD (Will et al.
1996; McLean et al. 1998; Ironside & Head 2004).
(j) Summary of CNS pathology
In general, there was very little pathological change in
the white matter, while the grey matter showed more
intense spongiosis and PrP deposition, which varied
remarkably between different brain regions. This is best
(a)
H&E
cerebellum
olive
cervical cord lumbar cord
GFAP PrP
PrP PrP
(k)
(b) (c) (d)
(g) (f) (e) (h)
(l) (i) (j)
Figure 3. Pathological changes in the kuru cerebellum, brain stem and spinal cord. The cerebellum (a) shows very little
spongiosis (mainly in the molecular layer (b)) and onlyoccasional kuru plaques (d). There is a generalized strong ﬁbrillary gliosis
in the white matter (c) of the Bergmann glia and, to a lesser extent, in the molecular layer. Deep grey matter structures of the
cerebellum (dentate gyrus, not shown) and the olives (f–h) show a remarkably intense deposition of synaptic PrP without the
presence of plaques (h). This is accompanied by strong ﬁbrillary gliosis (g). In the spinal cord (cervical (i) and lumbar segments
(k)), there are only very occasional plaques in the grey matter ( j,l). Scale bar, 120 mm( b–d,j,l) and 500 mm(f–h).
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which shows adjacent brain stem white matter
unstained and the grey matter of the olive containing
abnormal PrP. Cortical areas (ﬁgure 1a–g), hippo-
campus (ﬁgure 1o–q), cerebellum (ﬁgure 3a–d) and
spinal cord (ﬁgure 3i–l) were least affected, in that
there was very little or no spongiform change and often
very discrete PrP deposition. The most severely
affected structures were caudate nucleus and thalamus
(ﬁgure 1a,h–j,k–n), which were severely devastated
with massive spongiosis and neuronal loss, accom-
panied by a very severe astrocytic reaction and both
synaptic and plaque deposition of PrP. The thalamus
showed the heaviest deposition of synaptic PrP. Other
grey matter structures such as the cerebellar dentate
nucleus and the olive in the brain stem showed little
spongiosis, but a very strong gliosis and a diffuse and
intense deposition of PrP (ﬁgure 3e–h). In stark
contrast, cerebellar cortex, hippocampus and spinal
cord were almost unaffected by spongiosis or PrP
deposition. There were only occasional small dense
kuru plaques.
(k) Investigation of peripheral tissues
All peripheral tissues examined by immunohistochem-
istry comprising heart, pericardium, lung, muscle,
thymus, dura and cranial nerves 1–12 failed to show
detectable amounts of abnormal PrP deposition. To
investigate the lymphoreticular pathogenesis, 10% w/v
homogenates of spleen and distal ileum were investi-
gated by sodium phosphotungstic acid precipitation of
PrP
Sc (Safar et al. 1998; Wadsworth et al. 2001). This
method facilitates highly efﬁcient recovery and detec-
tion of PrP
Sc from human tissue homogenate when
present at levels 10
4–10
5-fold lower than found in brain
(Wadsworth et al. 2001, 2007; Frosh et al. 2004).
Nevertheless, despite analysis of several preparations of
tissue homogenate by this procedure, no detectable
PrP
Sc was found in spleen or distal ileum.
5. DISCUSSION
In the present study, we have investigated the
distribution of disease-related PrP in the CNS and in
peripheral tissue from a kuru patient who died in 2003.
Despite the unusually long incubation period in this
(b) (c)
(d) (f) (e)
(a)
sporadic CJD,
type 2 PrPSc 129MM
synaptic pattern, 
no plaques 
sporadic CJD,
type 3 PrPSc 129MV
synaptic pattern 
and small plaques
latrogenic CJD (GH)
type 3 PrPSc 129MV
frequent plaques, 
perineuronal PrP,
little synaptic PrP
kuru,
type 3 PrPSc 129MV
synaptic pattern and 
small plaques 
vCJD
type 4 PrPSc 129MM
synaptic pattern, dense plaques of variable size
and diffuse plaques
Figure 4. Comparison of abnormal PrP deposition in sporadic, iatrogenic and vCJD. The disease aetiology, PRNP codon 129
genotype of thepatient (M, methionine; V, valine) and the type of PrP
Sc detected in each sample (using theLondon classiﬁcation
of human PrP
Sc types; Collinge et al. 1996; Hill et al. 2003) are designated above each brain sample. Sporadic CJD with type 2
PrP
Sc 129 MM typically shows a diffuse, synaptic pattern of abnormal PrP deposition (a), while sCJD with type 3 PrP
Sc 129 MV
often forms small dense plaques (b). Propagation of type 3 PrP
Sc in iatrogenic CJD (caused by administration of contaminated
growthhormone, GH; c)and kuru(d) show not onlyvariably diffuse PrP deposition but alsostrikingformation of PrP plaques in
various areas of the brain. These PrP plaques are consistently distinct from those seen invCJD (e,f ), where PrP plaques are often
surrounded by conspicuous vacuolation, designated ‘ﬂorid plaques’.
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duced the central features described previously in kuru
(Fowler & Robertson 1959; Klatzo et al.1 9 5 9 ;
Neumann et al. 1964; Beck & Daniel 1965; Kakulas
et al. 1967; Hainfellner et al. 1997; Lantos et al. 1997;
McLean et al. 1998). Kuru shows neuropathological
changes that lie within the spectrum of those seen in
sCJD but is deﬁned by unusually prominent and
widespread unicentric PrP plaques. Kuru most closely
resembles iatrogenic CJD caused by peripheral admin-
istration of contaminated growth hormone (Brown
et al. 1992, 2000, 2006; Billette de Villemeur et al.
1994; Will 2003) and a rare subtype of sCJD associated
with long clinical duration, progressive ataxia and
PRNP codon 129 heterozygosity (Parchi et al. 1996,
1999; Hill et al. 2003).
Recently, we reported that kuru prions have
molecular and biological properties equivalent to
those of classical CJD prions rather than vCJD prions
(Wadsworth et al. 2008a). These ﬁndings support
previous molecular (Collinge et al. 1996; Parchi et al.
1997, 2000; Wadsworth et al. 1999; Hill et al. 2003,
2006), neuropathological (Will et al. 1996; McLean
et al. 1998; Ironside & Head 2004) and transmission
(Bruce et al. 1997; Hill et al. 1997; Asante et al. 2002;
Wadsworth et al. 2004; Bishop et al. 2006; Beringue
et al. 2008) studies indicating that vCJD is a highly
distinct human prion strain. The pathogenesis of vCJD
differs signiﬁcantly from that of other forms of human
prion disease. PrP
Sc is readily detectable in lympho-
reticular tissues in vCJD and not in classical CJD
or inherited prion disease (Hill et al. 1999, 2006;
Wadsworth et al. 2001; Glatzel et al. 2003; Head et al.
2004; Hilton et al. 2004; Joiner et al. 2005; Wroe et al.
2006). Here we now report no evidence for prion
colonization of lymphoreticular tissues in kuru, indicat-
ing that the peripheral pathogenesis of kuru is also
closely similar to classical CJD rather than vCJD. This is
in accordance with the negative tonsil biopsy reported
in an earlier kuru patient (Collinge et al. 2008).
Because kuru, iatrogenic CJD and vCJD are caused
by a peripheral route of exposure to infectious prions, it
has been speculated that extensive lymphoreticular
pathogenesis may result from this common route of
exposure. However, the fact that prominent lympho-
reticular infection has not been detected in iatrogenic
CJD (Hill et al. 1999; Head et al. 2004) or kuru (this
study) contradicts this hypothesis and indicates that
characteristic peripheral pathogenesis of vCJD is
deﬁned by prion strain type alone rather than route
of infection.
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